Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors.
Chawla S, Tabernero J, Kindler H, Chiorean E, LoRusso P, Hsu M, Haddad V, Bach B, Baselga J. Phase I evaluation of the safety of conatumumab (AMG 655) in combination with AMG 479 in patients (pts) with advanced, refractory solid tumors. Journal Of Clinical Oncology 2010, 28: 3102-3102. DOI: 10.1200/jco.2010.28.15_suppl.3102.Peer-Reviewed Original Research